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In vitro activity of quinupristin/dalfopristin against selected bacterial 
pathogens isolated in Italy 
Clin Microbiol Infect 1999; 5: 488-495 
Anna Marchese, Eugenio A .  Debbia and Gian Carlo Schito 
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Objective: To evaluate the activity of quinupristin/dalfopristin, a new injectable streptogramin, against 732 clinical 
strains recently isolated in Italy. 
Methods: Susceptibility tests were performed according to NCCLS-guided MIC methodology. Pathogens included 
in the evaluation included 108 Staphylococcus aureus isolates, 124 coagulase-negative staphylococcal isolates, 158 
Streptococcus pyogenes isolates, 30 streptococcus agalactiae isolates, 30 p-hemolytic streptococcal isolates, 18 
Streptococcus sanguis isolates, 80 Streptococcus pneumoniae isolates, 69 Enterococcal isolates, 40 Haemophilus 
influenzae isolates, 30 Moraxella catarrhalis isolates and, finally, 30 Gram-positive and 25 Gram-negative anaerobes. 
Results: Quinupristin/dalfopristin inhibited Staphylococcus aureus and other Staphylococcus spp., irrespective of their 
oxacillin or erythromycin resistance phenotypes. Similarly, streptococci were fully inhibited by quinupristin/dalfopristin. 
Enterococcus faecalis was not included in the spectrum of this streptogramin, while isolates of Enterococcus faeciurn 
were inhibited by the new compound. Respiratory pathogens such as H. influenzae and M. catarrhalis were inhibited by 
quinupristin/dalfopristin as well as all Gram-negative anaerobes tested. 
Conclusions: These findings suggest a putative role for quinupristin/dalfopristin in the empirical treatment of severe 
nosocomial and community-acquired infections caused by pathogens ofien displaying resistance to multiple antibiotics. 
This drug may provide an alternative to glycopeptide compounds. 
Key-words: Quinupristin/dalfopristin, Gram-positive pathogens, in vitro activity, Italian isolates 
INTRODUCTION 
Loss of susceptibility to previously effective drugs 
in Gram-positive organisms poses major therapeutic 
problems globally [l-41. In particular, this threat is 
represented by staphylococcal organisms, the etiologic 
agents dominating nosocomial infections, which, at least 
in Italy, express a high level ofmethicilhn and associated 
multiple resistance. Recent reports have suggested that 
staphylococcal species are evolving towards reduced 
susceptibility to vancomycin, the drug of choice in 
most infections [5-71. 
In Enterococcus, aminoglycoside resistance prevent- 
ing synergistic interactions with penicillin, and glyco- 
Corresponding author and reprint requests: 
Eugenio A. Debbia, Institute of Microbiology, 
University of Genoa, Largo Rosanna Benzi, 
10, 16132 Genoa, Italy 
Tel: +39 10 3537655 Fax: +39 10 504837 
E-mail: eugenio.debbia@aleph.it 
Accepted 18 February 1999 
peptide resistance, are established in some regions of the 
world [l], while in Streptococcus pyogenes, increased 
resistance to drugs such as the macrolides, the preferred 
alternative treatment to penicdlin, is posing therapeutic 
problems [8]. The viridans group of streptococci, while 
becoming increasingly important as a cause of 
bacteremia in the immunocompromised host, is 
becoming increasingly refractory to penicillin [9]. 
Similarly, the incidence of penicillin-resistant and 
multiresistant pneumococci is increasing worldwide 
[lo]. Increasing resistance is also apparent in com- 
munity-acquired Gram-negative organisms associated 
with respiratory tract infections, such as Haemophitus 
injuenzae and Moraxella catarrhalis, in which rates of 
ampicillin resistance due to synthesis of p-lactamases are 
often in excess of 30% [ l l ]  and 90% [12] respectively. 
The need for alternative drugs capable of over- 
coming the widespread resistance presented by primary 
nosocomial and community-acquired Gram-positive 
and respiratory Gram-negative pathogens is paramount. 
Quinupristin/dalfopristin (Synercid, RP 59500), a 
new injectable streptogramin, has shown promising 
bactericidal activity in in vitro tests on most refractory 
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Gram-positive aerobic and anaerobic organisms analyzed 
thus far 113-1 51. Its spectrum also encompasses Gram- 
negative respiratory pathogens and anaerobes [14,15]. 
Quinupristin/dalfopristin w d  soon be introduced 
for clinical usage in Italy, a country whose unique 
patterns of antibiotic prescription [16,17] have probably 
contributed to an epidemiology of resistant pathogens 
that differ somewhat from that in other European 
nations [18]. For this reason, and in order to investigate 
the efficacy and potency of this new drug on clinical 
isolates representing a specific resistance phenotype, we 
undertook this ad hoc investigation, pedormed during 
1996-97. 
MATERIALS AND METHODS 
Bacterial strains 
Recently isolated non-duplicate nosocomial and com- 
munity-acquired pathogens were included in the study. 
Numbers of organisms studied and specific resistance 
phenotypes are shown in Tables 1-7. 
Susceptibility tests 
The drugs tested varied according to the species 
considered, as shown in Tables 1-7. They were supplied 
by the manufacturers: quinupristin/daKopristin (Rh6ne- 
Poulenc Rorer, Milan, Italy); penicillin (Bristol-Myers 
Squibb, Rome, Italy); ceftriaxone (Roche, Milan, 
Italy); ciprofloxacin (Bayer, Milan, Italy); erythromycin 
(Abbott, Campoverde, Italy); vancomycin (Ldy, Sesto 
Fiorentino, Italy); teicoplanin (Lepetit, Gerenzano, 
Italy); gentamicin (Schering-Plough. Milan, Italy); 
amoxycillin-clavulanate (SmithKline Beecham, Milan, 
Italy); oxacillin, cefoxitin, doxycycline, clindamycin, 
chloraniphenicol and metronidazole (Sigma, Milan, 
Italy). Sterile stock solutions of the antibiotics were 
prepared from the standard reference powders in 
accordance with the instructions received. 
Minimum inhibitory concentrations (MICs) of the 
antimicrobial agents were determined by the agar 
dilution method following the procedure defined by 
the National Committee for Clinical Laboratory 
Standards, using Mueller-Hinton agar (Difco Labora- 
tories, Detroit, MI, USA) as test medium 1191. For tests 
performed with streptococci, 5% defibrinated lysed 
horse blood was added to the Mueller-Hinton medium, 
whereas for evaluation of H. irtfluenzae, Haemophilus 
Test Medium (HTM) was employed. MICs of 
anaerobic bacteria were determined by the agar 
dilution method following the NCCLS procedure 1201, 
using Wilkins-Chalgren agar (Difco Laboratories) as 
test medium. Plates containing antibiotic and control 
plates (no antibiotic) were incubated in an anaerobic 
chamber at 36OC for 48 h. The MIC was defined as the 
lowest concentration of antibiotic that yielded no 
visible growth. 
The following organisms were included in the assays 
for quality control: Escherickia coli 25922, Staphylococcus 
aureus 29213, Enterococcus faecalis 29212, Pseudomanas 
aeruginosa 27852, Streptococcus pnerimoniae 496 19, H. 
iry'luenzae 49247, Bacteroidesjagilis 25285 and Bacteroides 
thetaiotaomicron 229741. 
RESULTS 
The in vitro susceptibilities of staphylococci to 
quinupristin/dalfopristin and to other drugs tested are 
shown in Table 1. Oxacillin-sensitive (oxaS) Stuphylo- 
coccus aureus strains were all inhibited by quinupristin/ 
dalfopristin at 0.5 mg/L, while the oxacillin-resistant 
(oxaR) Staphylococcus aureus isolates were inhibited at 
concentrations of 1 mg/L. 
Against coagulase-negative staphylococci (CNS), 
all drugs showed patterns of activity similar to those 
with Staphylococcus airreus. Overall, against all staphylo- 
coccal species, quinupristin/dalfopristin, teicoplanin 
and vancomycin qualified as the most potent antibiotics 
(100% of strains inhibited). Except for erythromycin, 
Streptococcus pyogenes strains, irrespective of their resist- 
ance phenotype, and other P-hemolytic streptococci 
(Tables 2 and 3) were exquisitely susceptible to all the 
compounds assayed, with 100% of the strains inhibited 
and with MIC9" values ranging from -4.06 to 0.25 
mg/L. The other streptococci studied, including 18 
representatives of Streptococcrrs sangtiis (Table 3), were 
totally inhibited by quinupristin/dalfopristin and the 
other compounds assayed. 
All Streptococcns pneuinoniae strains tested were 
inhibited by 1 mg/L of quinupristin/dalfopristin ir- 
respective of their resistance to penicillin and/or 
erythromycin (Table 4). Penicillin-resistant and inter- 
mediate isolates were poorly inhibited by erythromycin 
(30-50% of susceptible strains) and ciprofloxacin 
(MIC50=2 mg/L). Moreover, only ciprofloxacin 
(MIC90=2 mg/L) was less potent than the other drugs 
against erythromycin-resistant pathogens. Table 5 sum- 
marizes the results of the susceptibility tests carried 
out with the enterococci. Vancomycin-susceptible 
(vans) Enterococcirsfaecalis strains were not susceptible to 
quinupristin/dalfopristin and erythromycin, while 
teicoplanin and vancomycin, as expected, inhibited all 
the isolates. The few representatives (five isolates) of 
vancomycin-resistant (vanR) Enterococcus fdecalis were 
refractory to all the drugs examined. Vans Enterococcus 
faecium isolates were inhibited by quinupristin/ 
dalfopristin (82%), gentamicin (7 l%), doxycycline 
(41%) and ciprofloxacin (l2%), while this species was 
fully susceptible to both teicoplanin and vancomycin. 
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Table 1 In vitro activity of quinupristin/dalfopristin and other drugs against 332 Staphylococcus strains 
CNS 
oxaS (68) 
CNS 
oxaR (56) 
Staphylococcus aureus Quinupristin/dalfopristin 
oxaS (38) Clindamycin 
Erythromycin 
Oxacillin 
Ciprofloxacin 
Teicoplanin 
Vancomycin 
Staphylococcus aureus Quinupristidddfopristin 
oxaR (70) Clindamycin 
Erythromycin 
Oxacillin 
Ciprofloxacin 
Teicoplanin 
Vancomycin 
Quinupristin/dalfopris tin 
CEndamycin 
Erythromycin 
OxaciUin 
Ciprofloxacin 
Teicoplanin 
Vancomycin 
Quinupristin/ddfopristin 
Clindamycin 
Erythromycin 
Oxacillin 
Ciprofloxacin 
Teicoplanin 
Vancomycin 
0.06-0.5 
0.25-0.5 
0.06 to >128 
0.12-2 
0 . 1 2 4 4  
0.25-2 
0.5-1 
0.12-1 
0.25 to 2128 
0.12 to >128 
8 to >128 
8 4 4  
0.25-4 
0.5-1 
0.06-0.5 
0.06 to >128 
0.12 to >128 
0.06-2 
0.0644 
0.12-2 
0.25-2 
0.12-0.5 
0.12 to 2128 
0.12 to >128 
4 to >128 
0.12-64 
0.5-8 
1-2 
0.12 
0.5 
0.25 
0.25 
0.25 
0.5 
0.5 
0.5 
128 
128 
128 
16 
1 
0.5 
0.12 
0.25 
0.25 
0.25 
0.25 
1 
1 
0.12 
>I28 
2128 
128 
16 
2 
2 
0.25 
0.5 
0.25 
0.5 
0.5 
1 
0.5 
0.5 
>128 
>128 
>128 
16 
2 
0.5 
0.5 
>128 
>I28 
2 
8 
2 
0.5 
7 
I 
>128 
>128 
>128 
32 
8 
2 
100 
100 
100 
100 
100 
100 
30 
20 
0 
12.8 
100 
100 
100 
75 
75 
100 
75 
100 
100 
100 
25 
21.4 
0 
16 
100 
100 
89.4 
97.3 
~~~~~ ~ ~~~~ ~~ 
oxas, oxacdin susceptlble, ox&, oxacillin resistant, CNS, coagulase-negative staphylococci. 
"According to NCCLS [19] guidelines, Barry et a l  [37] and Tenover and Baker [38] 
The seven isolates of vanR Enterococcets faecium were 
poorly susceptible to all antimicrobial agents con- 
sidered, although quinupristin/dalfopristin showed the 
lowest MIC range (0.25-8 mg/L). 
The data obtained from Gram-negative respiratory 
pathogens tested are displayed in Table 6. H. infZuenzae 
showed high susceptibility to all the antibiotics 
examined in terms of both MIC90 values and 
percentage of strains inhibited (100%). 
M. ciltarrhalis remained susceptible to quinupristid 
dalfopristin and all other agents, irrespective of p- 
lactamase production. The concentration of quinu- 
pristin/dalfopristin inhibiting 90% of Gram-positive 
anaerobes was 0.25 mg/L (Table 7), while that for 
metronidazoIe and vancomycin was 1 mg/L and that 
for chloramphenicol was 4 mg/L. 
DISCUSSION 
The susceptibility of oxacillin-resistant staphylococci to 
quinupristin/dalfopristin is of special interest, since the 
proportion of oxacillin-resistant and multiresistant 
strains exceeds 34% in Italy [21] and appears to be 
increasing [22]. Staphylococci are the only major 
pathogens in which the incidence of resistance is 
directly comparable to the figures reported for other 
European countries [21]. These microorganisms are 
particularly difficult to treat, as they are not only 
insensitive to all p-lactam antibiotics but they are also 
generally refractory to other classes of drugs such as 
macrolides, rifampin, tetracycline and fluoroquino- 
lones [1,4,23]. Reports suggest that the widespread use 
of vancomycin is selecting poorly susceptible Staphylo- 
coccus aureus in areas where this is the only glycopeptide 
available, although the stage of full resistance has not 
yet been reached [6,7]. The use of quinupristid 
dalfopristin may therefore be beneficial in the treatment 
of infections sustained by oxacillin- and/or vanco- 
mycin-resistant staphylococci, should they appear. 
If widely employed, quinupristin/dalfopristin may 
diminish the strong selective pressure presently exerted 
by the glycopeptides. 
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Table 2 In vitro activity of quinupristiddalfopristin and other drugs against 158 Stveptococcus pyogenes strains 
~~ ~~ ~ 
YO susceptible 
Organism Range MICio MICW at recommended 
(number tested) Antibiotic (mg/L) ( W L )  ( m g 4  breAkpoint” 
Streptococcus p y o p e s  
eryS (68) 
Strrpfptacocnrs p y o p e s  
eryK (I )  (30) 
Streptooccus pyqc’nes 
eryK (M) (30) 
Quinupristin/dalfopristin 
Penicillin 
Ceftriaxone 
Erythromycin 
Ciprofloxacin 
Vancomycin 
Quinupristin/dalfopristin 
Penicillin 
Ceftriaxone 
Erythromycin 
Ciprofloxacin 
Vancomycin 
Quinupristin/dalfopris tin 
Penicillin 
Ceftriaxone 
Erythromycin 
Cipi-ofloxacin 
Vanconiycin 
Quinupristin/ddfopristin 
Penicillin 
Ceftriaxone 
Erythromycin 
Ciprofloxacin 
Vancomycin 
50.06 
50.06 
50.06 
50.06-0.125 
0.25 
0.25 
5 0.06-n. 25 
50.06 
50.06 
64 to >64 
0.25-0.5 
0.25 
50.06-0.115 
50.06 
50.06 
32 to >64 
0.25 
0.2s 
5 0.06-0.115 
5o.nh 
50.06 
16-32 
0.125425 
0.15 
50.06 
50.06 
50.06 
0.125 
0.25 
50.06 
50.06 
50.06 
0.25 
0.25 
0.125 
n.25 
>64 
50.06 
50.06 
>64 
0.25 
0.25 
50.06 
50.06 
50.06 
0.25 
16 
0.25 
50.06 
50.Oh 
5 O . O t l  
0.25 
0.25 
0.125 
n.125 
50.Oh 
50.06 
0.25 
0.25 
0.125 
>64 
50.06 
50.0b 
0.25 
0 2s 
50.06 
50.06 
50.06 
0.25 
0.25 
>64 
16 
100 
100 
100 
1 ( )O 
100 
101) 
100 
100 
1 on 
0 
100 
1110 
1 on 
100 
I on 
0 
100 
100 
100 
100 
100 
100 
1 0(1 
0 
eryS, erythromycin susceptible; eryR, erythromycin resistant. Phenotypes: C, constitutive; I, inducible; M. efflux [39]. 
’According to NCCLS [lY] guidelines, Barry et a1 [37] and Tenover and Baker [38]. 
Table 3 In vitro activity of quinupristin/dalfopristin and other drugs against 78 P-hemolytic Streptococcus strains and 
Streptococcus sanguis 
‘% susceptible 
Organism Range MICx MICWJ at recommended 
(number tested) Antibiotic (mg/L) (ing/L) (mg/L) breakpoint a 
Streptococcus qalartiar 
(30) 
Qui~iupristin/dalfopristin 
Erythromycin 
Penicillin 
Ceftriaxone 
Vancomycin 
Ciprofloxacin 
Quinupristdddfopristin 
Erythromycin 
Penicillin 
Ceftriaxone 
Vancomycin 
Ciprofloxacin 
Quinupristin/dalfopristin 
Erythromycin 
Pcnicillin 
Ceftriaxone 
Van comycin 
Ciprofloxacin 
0.25 
50.06 
50.06 
0.125-0.25 
0.15-0.5 
0.5-1 
0.25-1 
50.06-0.25 
50.06-0.125 
5 0.06-0.125 
0.5-1 
0.5-1 
0.5-1 
50.06 
50.06 
50.06 
0.5 
1 
0.25 
0.25 
50.06 
0.5 
1 
0.5 
0.125 
50.06 
50.06 
1 
1 
1 
50.06 
50.06 
50.06 
0.5 
1 
50.06 
0.25 
0.25 
50.06 
50.06 
0.i  
1 
1 
0.25 
0.115 
0.125 
1 
1 
1 
50.06 
50.06 
SO.06 
0.5 
1 
100 
1 00 
100 
100 
10n 
1 00 
1 00 
100 
100 
100 
100 
100 
10(1 
100 
100 
100 
100 
1 00 
p-Hemolytic Streptococcus isolates C 6, G 18, and F 6. 
See also Tables 1 and 2. 
”According to NCCLS [lY] guidelines, Barry et a l  [37] and Tenover and Baker [38]. 
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Table 4 In vitro activity of quinupristiddalfopristin and other drugs against 70 Streptocoms pneumoniae strains 
% susceptible 
Organism Range MICso M I G O  at recommended 
(number tested) Antibiotic ( m g 4  (mg/L) (mg/L) breakpoint" 
Streptococcus pneumoniae 
pens (40) 
Streptococcus pueumoniue 
pen1 (10) 
Streptococcus pneumoniae 
penR (10) 
Streptocoms pneumoniae 
eryR (10) 
Quinupristin/dalfopristin 
Penicfin 
Cefiriaxone 
Ciprofloxacin 
Erythromycin 
Vancomycin 
Quinupristin/dalfopristin 
Penicilhn 
Ceftriaxone 
Ciprofloxacin 
Erythromycin 
Vancomycin 
Quinupristin/dalfopristin 
Penicfin 
Cefiriaxone 
Ciprofloxacin 
Erythromycin 
Vancomycin 
Quinupristin/dalfopristin 
Penicfin 
Ceftriaxone 
Ciprofloxacin 
Erythromycin 
Vancomycin 
0.5-1 
5 0.007-0.015 
50.125 
0.5-2 
10.125 
50.1 25-0.25 
0.5-1 
0.12-1 
S O .  12-0.5 
1-4 
0.25 to >128 
10.125-0.25 
0.5-1 
2 4  
0.5-1 
0 . 5 4  
0.5 to >I28 
50.125-0.25 
0.5-1 
50.125 
1-2 
8-64 
5 0.007-0.06 
50.125-0.25 
0.5 
50.007 
S0.125 
50.125 
50.125 
1 
1 
0.12 
0.5 
2 
3 28 
50.125 
1 
2 
0.5 
2 
0.5 
0.25 
0.5 
50.007 
10.125 
1 
64 
50.125 
1 
50.007 
10.125 
2 
10.125 
0.25 
1 
1 
0.5 
4 
>128 
0.25 
1 
2 
0.5 
4 
128 
0.25 
1 
0.06 
50.125 
3 
64 
0.25 
100 
100 
100 
100 
100 
100 
0 
100 
20 
100 
100 
0 
60 
50 
100 
100 
100 
100 
0 
100 
- b 
- b 
pens, penicillin susceptible; pen1, penicillin intermediate; penR, penicillin resistant; eryR, erythromycin resistant, 
"According to NCCLS recommended guidelines [19], Barry et al [37] and Tenover and Baker [38]. 
bNo breakpoint avadable in NCCLS guidelines. 
The same assumption may hold true for multi- 
resistant enterococci, which while a common cause of 
nosocomial infections, at present rarely display 
glycopeptide resistance in Italy [24]. Glycopeptide 
resistance is known to accumulate preferentially in 
Enterococcus faecium. The role of quinupristin/dalfo- 
pristin seems, therefore, even more attractive, since this 
is the clinically important species on which the new 
drug exerts a useful activity, a fact also anticipated in 
the literature [13,25]. 
Streptococcus pyogenes remains fully susceptible to 
penicillins and other p-lactams [26]. However, its 
sensitivity to macrolides has been known to vary and 
has increased in certain regions [83. In Italy, various 
recent surveys have placed overall resistance to erythro- 
mycin in Streptococcus pyogenes at  around 40% [27-291. 
This present increased incidence of macrolide resistance 
in our country resembles a similar episode described 
several years ago in Japan [30], although a mechanistic 
explanation for its occurrence has yet to be demon- 
strated. In particular, about 40% of the erythromycin- 
resistant strains now circulating show the high-level 
constitutive phenotype that diminishes the efficacy of 
14-, 15-, and 16-membered macrolides, lincosamides 
and streptogramin B [8].  Quinupristin/dalfopristin, 
which has been found to overcome not only inducible 
(I) and M-type but also constitutive macrolide resist- 
ance, might be employed in serious infections caused 
by Streptococcus pyogenes in areas such as Italy, where this 
trait has become widespread. 
Multiresistance in Streptococcus pneumoniae is a 
universal problem [lo]. This microorganism is respon- 
sible for several important infections and remains a 
leading cause of morbidity and mortality worldwide 
despite the availability of several antimicrobial agents 
that perform adequately in vitro [31]. Although, for 
non-meningitic infections, high-dose penicillin remains 
clinically effective [32], this type of treatment is risky 
and may not always be successful [33,34]. If penicillin 
resistance increases to levels exceeding 4 mg/L in 
routine isolates of this pathogen, therapy with other 
drugs will become necessary [35]. In Italy, the inci- 
dence of penicillin-resistant Streptococcus pnetrrnoniae has 
remained relatively low (14.3%), in this country, 50% 
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Table 5 In vitro activity of quinupristin/dalfopristin and other drugs against 69 enterococci 
"/n susceptible 
Organism Range MICso MIC90 at recommended 
(number tested) Antibiotic (mg/L) (mg/L) (mg/L) breakpoint" 
Entcroioccus faecalis 
vans (40) 
Enterococcus faecalts 
vanR (5) 
Enferococcus j k i u m  
vans (17) 
Enteroioccus jaecirrm 
vanR (7) 
Quinupristin/dalfopristin 
Gentamicin 
Ciprofloxacin 
Erythromycin 
Doxycycline 
Vancomycin 
Teicoplanin 
Quinupristin/dalfopristin 
Gentamicin 
Ciprofloxacin 
Erythromycin 
Doxycycline 
Vancomycin 
Teicoplamn 
Quinupristin/dalfopristin 
Gentamcin 
Ciprofloxacin 
Erythromycin 
Doxycycline 
Vancomycin 
Teicoplanin 
Quinupristin/dalfopristin 
Gentamicin 
Ciprofloxacin 
Erythromycin 
Doxycycline 
Vancomycin 
Teicoplanin 
0.25-8 4 8 5 
8 to >500 16 >500 80 
0.5-64 1 32 75 
0.06 to >I28 64 >128 2.5 
0.12-32 16 32 22.5 
0.5-4 1 4 100 
0.06-1 0.25 0.5 100 
4-8 
8 to >500 
64 to >I28 
8-64 
16-32 
128-256 
16-128 
0 .124  
2 to >500 
1 to >128 
0.5 to >128 
0.06-32 
0.54 
0.12-0.5 
0.25-8 
2 to >500 
2 to >128 
1-64 
8-32 
256 
6C256 
0.5 
16 
4 
128 
8 
1 
0.2s 
1 
>500 
128 
2128 
16 
3 
1 
0.5 
82 
70 
41 
0.05 
41 
100 
100 
vans, vancomycin susceptible; vanR, vancomycin resistant. 
'According to NCCLS recommended guidelines [19], Barry et al [37] and Tenover and Baker [38] 
Table 6 In vitro activity of quinupristin/dalfopristin and other  drugs against 70 respiratory Gram-negative aerobes 
% susceptible 
breakpointa 
Organism Range MIC5ri MIC9" at recommended 
(number tested) Antibiotic (mg/L) (mg/L) (mg/L) 
Haemophihs influenrae Quinupristiddalfopristin 1-8 
('Wb Amoxycillin/clavulanate 0.12-1 
Erythromycin 0.54 
Ceftriaxone 0.06 
Ciprofloxacin 0.03-1 
2 
0.5 
2 
0.06 
0.03 
2 95 
0.5 100 
4 NA 
0.06 100 
0.03 100 
hloraxella catarrhalis Quinupristin/dalfopristin 0.06-0.25 0.25 1)25 100 
(30)' AmoxyciUin/clavulanate 0.12-0.25 0.12 0.25 100 
Erythromycin 0.06-0.5 0.25 0.25 100 
Ciprofloxacin 0.03-0.06 0.03 0.06 100 
Ceftriaxone 0.06-1 0.5 1 100 
NA, not applicable. 
"According to NCCLS recommended guidelines [19], Barry et al [37] and Tenover and Baker [38]. 
hIncluding eight P-lactamase-producing strains. 
'Including 13 p-lactamase-producing strains. 
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Table 7 In vitro activity of quinupristin/dalfopristin and other drugs against 55 anaerobes 
Organism 
(number tested) Antibiotic 
Gram-positive (30)b Quinupristin/dalfopristin 
Metronidazole 
Chloramphenicol 
Erythromycin 
Cefoxitin 
Clindamycin 
Vancomycin 
Gram-negative (25)‘ Quinupristin/dalfopristin 
Metronidazole 
Chloramphenicol 
Erythromycin 
Cefoxitin 
Clindamycin 
0.06-2 
0.06-0.5 
0.25-32 
0.5 to >128 
0.12 to >128 
0.5-128 
0.25-2 
0 . 0 6 4  
0.12-8 
0.5-64 
0.5 to >I28 
0.12 to 2128 
0.5-32 
0.12 
0.25 
0.5 
0.5 
1 
0.12 
0.5 
1 
0.5 
2 
8 
8 
2 
0.25 
0.25 
4 
>128 
128 
>S28 
1 
2 
0.5 
4 
>128 
32 
>128 
97 
93 
73 
67 
77 
100 
72 
96 
24 
84 
52 
i no 
1 no 
aAccording to NCCLS recommended guidelines [20], Barry et al [37], and Tenover and Baker [38]. 
Peptostreptoroccus micros 2. 
‘Barteroidesfragilis 13, Bacteroides vulgatus 3, Bucteroides dirtasonis 3, Bacteroides thetaiotaomicron 6. 
Clostridium d@le 24, Eubacteriuni lenturn 1, Peptostreptococcus magnus 1, Peptostreptococcus anaerobious 1, Peptostreptococcus asaccharolyticus 1, 
of these organisms display insensitivity to the available 
injectable third-generation cephalosporins [18]. Given 
the possibility of further spreading driven by the high 
consumption of these drugs in our country [16], 
therapy of the more severe infections (meningitis, 
septicemia) might eventually become exceedingly 
difficult. Considering the exquisite susceptibility of 
these isolates to quinupristin/dalfopristin, as well as the 
penetration of this molecule in cerebrospinal fluid [36] 
of animal models, the new injectable streptogramin 
may represent a good therapeutic option in difficult- 
to-treat conditions if these findings are confirmed in 
humans. 
The fact that Gram-negative pathogens such as H. 
infuenzae and M .  catarrhalis and most Gram-positive 
anaerobes are easily inhibited by quinupristin/dalfo- 
pristin extends the usefulness of the new drug, which 
may thus encompass respiratory and mixed infections. 
Taken together, these findings suggest a role for 
quinupristin/dalfopristin in the empirical treatment of 
a broad range of nosocomial and community-acquired 
infections deemed to be sustained by pathogens often 
characterized by multiple antimicrobial resistance. 
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